ストックスクリーナーアプリを入手
0.00
100.00%
-0.1743
アフターアワーズ：
.07
0.07
+
前日終値:
$0.1743
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$N/A
収益：
$34.56M
当期純損益:
$-123.33M
株価収益率:
0.00
EPS:
-0.383
ネットキャッシュフロー:
$-90.46M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-75.91%
1年 パフォーマンス:
-82.72%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.185
52週間の値動き範囲:
$0.00
$0.2249
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Compare SGMO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.00 | 0 | 34.56M | -123.33M | -90.46M | -0.383 |
VRTX
Vertex Pharmaceuticals Inc
|
475.20 | 118.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
623.43 | 64.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.50 | 53.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.06 | 38.48B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.77 | 36.04B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-12-13 | アップグレード | Truist | Hold → Buy |
| 2024-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-02-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-01-07 | 再開されました | Guggenheim | Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-12-16 | 再開されました | H.C. Wainwright | Buy |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | SunTrust | Buy |
| 2019-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2018-10-10 | 開始されました | Guggenheim | Buy |
| 2018-06-20 | 開始されました | BofA/Merrill | Buy |
| 2017-11-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2016-11-01 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-10-19 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-10-23 | 再開されました | Jefferies | Buy |
| 2013-05-03 | 開始されました | BioLogic Equity Research | Sell |
| 2011-02-23 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-07-29 | 繰り返されました | Wedbush | Outperform |
| 2009-10-19 | 開始されました | Brean Murray | Sell |
| 2009-10-07 | 繰り返されました | Leerink Swann | Outperform |
| 2009-08-25 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Sangamo Therapeutics Inc (SGMO) 最新ニュース
Gene Therapy Co. Sangamo Gets Initial OK For $30M DIP - Law360
A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech - inc.com
Biotech firm files for bankruptcy with $115M debt; Eli Lilly, Astellas bet on it anyway - MassLive
Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro
Inside Sangamo Therapeutics' bankruptcy: Dwindling choices, millions of dollars, more layoffs - The Business Journals
Sangamo files for bankruptcy as Lilly and Astellas target assets - The Pharmaletter
Paul Weiss Advises Lilly on Sangamo Chapter 11 Bid - Lawyer Monthly
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor - Yahoo Finance
Eli Lilly Enters Into Agreement to Acquire Sangamo Assets as Stalking Horse Bidder in Chapter 11 Auction - Paul, Weiss
Sangamo Therapeutics | 8-K/A: Current report (Amendment) - Moomoo
Sangamo Therapeutics | 8-K: Current report - Moomoo
Form 8K Sangamo Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle - Benzinga
UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy - BioSpace
Eli Lilly And Company entered into asset sale agreement to acquire Certain Assets from Sangamo Therapeutics, Inc.. - marketscreener.com
Sangamo files for Chapter 11, signs asset sale deals with Lilly - Investing.com UK
A Gene Therapy Biotech Firm Has Filed for Chapter 11 Bankruptcy - WhatNow
Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans - Law360
Sangamo Therapeutics Initiates Chapter 11 and Asset Sales - TipRanks
Sangamo Therapeutics files for bankruptcy after unique 30-year run - The Business Journals
Sangamo Therapeutics files for Chapter 11 bankruptcy - MSN
Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas - TradingView
Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection - citybiz
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas - The Manila Times
Sangamo Therapeutics (SGMO) Files for Chapter 11 Bankruptcy Prot - GuruFocus
Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets - Seeking Alpha
Sangamo Therapeutics, Inc. Filed for Bankruptcy - marketscreener.com
Sangamo Therapeutics(SGMO) Stock Options Chain | Quotes & News - Moomoo
Sangamo Therapeutics Inc (SGMO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sangamo Therapeutics Inc (SGMO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sangamo Therapeutics Inc (SGMO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sangamo Therapeutics Inc (SGMO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sangamo Therapeutics (SGMO) Hovers at $0.15: Biotech Micro-Cap Stuck in Tight Trading RangeQuality ETF - Město Břeclav
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy - Benzinga
Fabry Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutic - Barchart.com
Sangamo Therapeutics explores strategic alternatives after burning through $1.6 billion - The Business Journals
Sangamo hires Raymond James to explore strategic alternatives By Investing.com - Investing.com Australia
Sangamo hires Raymond James to explore strategic alternatives - Investing.com
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders - The Manila Times
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jain Nikunj - Moomoo
Sangamo (SGMO) executive shares withheld to cover RSU tax obligations - Stock Titan
Sangamo (SGMO) SVP surrenders 4,036 shares for RSU tax withholding - Stock Titan
Sangamo (SGMO) SVP uses 4,036 shares to cover RSU tax - Stock Titan
Sangamo Therapeutics (SGMO) CEO surrenders RSU shares to cover taxes - Stock Titan
Sangamo presents primate data for prion suppressor ST-506 - BioWorld News
Sangamo Therapeutics (SGMO) reports Q1 loss, misses revenue estimates - MSN
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period - TipRanks
Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha
Finance Watch: Sangamo Once Again Nearing The End Of Its Cash - Citeline News & Insights
Sangamo Therapeutics | SCHEDULE 13G: Others - Moomoo
Sangamo Therapeutics Inc (SGMO) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
5.59%
大文字化:
|
ボリューム (24 時間):